Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03989180
Other study ID # CL-SY-01-0092
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 6, 2016
Est. completion date December 6, 2020

Study information

Verified date February 2022
Source Check-Cap Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

To evaluate the performance of Check-Cap Imaging System in healthy volunteers in a variety of operating scenarios. The Back recorder unit is the primary module for evaluation The participants DO NOT ingest a capsule and the capsules do not have any radioactive source


Description:

1. st visit - Subjects will be referred to the study by an advertisement in the local media - The subjects will receive a preliminary explanation about the study procedure and required activities. If the subjects agree to participate in the study will be asked to sign the ICF - Subjects will be screened for eligibility according to the inclusion/exclusion criteria. - The date for their participation will be coordinated at their convenience 2. nd visit - Subject will arrive to the company R&D lab and will receive detailed introduction about the procedure and instruction for the daily activities. (The total duration of Check-Cap Imaging System study for each subject is up to 4 days). - Subjects will receive detailed instructions (verbally and written) about the normal operation of the C-Scan System and how to handle it during normal daily routine. They will be asked to document all their daily activity in a personal diary. - The C-Scan Track will be attached to their lower back to test its functionality and the capsule will be attached to their abdomen to test the effect on data transmission during daily activities. - The interference of the back recorder with the cloths (belt, bra etc.) will be monitored for any discomfort. - Subjects will be asked to complete a personal diary which documents the time and duration of significant activities during the procedure such as meal times, sleeping times, physical activities etc. - Some subjects will be instructed to be stationary during short sessions (10-20-30 min) and may read, watch TV or use the Internet. The localization data will be collected on a dedicated portable computer via these detectors. - The monitoring routine for each subject will include but not limited to the following parameters: - The well-being of the subject, and his/her daily routine: work, meals, driving, public transportation, mild sport, shower, sleep, other activities - Inquiries about any discomfort caused by the recorder - Inquiries about any discomfort or skin irritation caused by the patches. - Inquiries about the function of the recorder as indicated by the recorder visual & indicators - Ease of operation of the push buttons positioned on the recorder (reaching to the lower back with w/out direct vision (mirror) - Responding to auditory and visual indicators position on the recorder - Some subjects will be asked to continue carrying the back recorder system for few more days in order to evaluate the effects of the system on their daily activities. - A subjective questionnaire will be filled by the subjects following each phase of the evaluation in order to solicit immediate feedback regarding any discomfort or complaint During the current development study the plan is to simulate some of these scenarios and evaluate the functionality of the back-recorder and communication with the capsule - Subjects will continue their daily routine: work, sleep, shower, driving in car or public transportation, sit, stand, walk. - Subjects should refrain from active sport such as jogging, physical exercise in the gym, swimming, sauna, any ball-games, skiing etc. - Subjects should refrain from Flights, boat trips or long train travels during the monitoring procedure - Subjects should try and stay away from areas with high electromagnetic fields such as: High voltage elect. Poles, transformation station, radio and TV transmitter station etc. - Subjects should not be examined by CT or MRI (unless it is an emergency) - Subjects who are working in an area with high electromagnetic field should not be examined by the capsule


Recruitment information / eligibility

Status Completed
Enrollment 76
Est. completion date December 6, 2020
Est. primary completion date December 6, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 75 Years
Eligibility Inclusion Criteria: - Male or female between 20 and 75 years of age - Subjects who are generally healthy - Subjects who fit the following body dimensions: - Height: 150-200 cm - Weight : 50-140 Kg - BMI: 20-35 - Subjects who are ready to follow the various physical activities such as: walking, running, sitting, driving, bending etc. - Subjects who are free to spend up to 4 days carrying the back recorder system. - Sign informed consent Form. Exclusion Criteria: - Subjects with cancer or other life threatening diseases or conditions - Pregnant women - Subjects with cardiac pacemaker or any other implanted or external portable medical device (i.e. infusion pumps) - Bed-ridden or sedentary subjects - Subjects who suffer significant movement limitations (who cannot follow the typical activities of walking, driving, bending, sitting etc.) - Morbid Obesity (BMI > 35) - Subjects under custodial care - Participation in current clinical study or clinical study within 30 days prior to the procedure

Study Design


Related Conditions & MeSH terms


Intervention

Device:
C-Scan System
Subjects will receive detailed instructions (verbally and written) about the normal operation of the recorder and how to handle it during normal daily routine. They will be asked to document all their daily activity in a personal diary (attached) The recorder will be secured to their lower back to test its functionality

Locations

Country Name City State
Israel Bnai-Zion Medical Center Haifa

Sponsors (1)

Lead Sponsor Collaborator
Check-Cap Ltd.

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Performance of the C-Scan system in terms of communication between the C-Scan Capsule and the System Track in different locations, positions and configurations. The C-Scan System performance will be tested in different versions, configurations and locations. The C-Scan Cap with no radioactive source will be placed on the subject's abdomen and the C-Scan Track will be placed on the subject's back in different locations. The subject will be ask to continue his/her rutine daily activities such as: sleeping, driving a car, watching TV etc for a few days. 36 months
See also
  Status Clinical Trial Phase
Recruiting NCT05074966 - The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts Phase 3
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Suspended NCT05124743 - HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Recruiting NCT05056389 - Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA) Phase 1
Completed NCT04551001 - Evaluation of Cold Forcep and Cold Snare Polypectomy for Polyps Less Than or Equal to 3mm in Size During Colonoscopy N/A
Completed NCT04551014 - Evaluation of EverLift in the Performance of Polypectomy for Polyps 4-9mm N/A
Recruiting NCT04270500 - The Impact of Physical Exercise on Sleep in Colorectal Cancer Patients During Prehabilitation Period N/A
Recruiting NCT03667911 - Virtual Reality Videos in Improving Bowel Preparation Quality of Colonoscopy N/A
Not yet recruiting NCT04073680 - A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05572684 - A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors Phase 1/Phase 2
Suspended NCT04108481 - Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer Phase 1/Phase 2
Completed NCT03567850 - Problem Solving Skills Training in Adult Cancer Survivors: Bright IDEAS-AC N/A
Recruiting NCT05870332 - Nationwide Study of Artificial Intelligence in Adenoma Detection for Colonoscopy
Completed NCT04534218 - Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer Phase 2
Enrolling by invitation NCT05590117 - Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer Early Phase 1
Recruiting NCT03129139 - A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelideā„¢ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors Phase 1
Completed NCT04195646 - Computer Aided Detection of Polyps During Colonoscopy Procedures N/A
Not yet recruiting NCT03618329 - Effect of Prehabilitation on the Lean Mass Index (IMM) in ERAS PROGRAMM. N/A
Not yet recruiting NCT03261752 - New Genes in the Carcinogenesis of Colorectal Cancer
Terminated NCT03621982 - Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Phase 1